• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer.
【24h】

Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer.

机译：治疗肺癌的老人。非小细胞肺癌。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There is a general trend worldwide of an increasing incidence of elderly population. Age is the greatest risk factor for cancer; therefore, this demographic shift is the main reason for an increase of cancer incidence. Lung cancer is a typical disease of the elderly patients. This review summarizes the issues of treatment of non-small cell lung cancer (NSCLC) in the elderly. Early stage NSCLC is usually treated with radical surgery, locally advanced NSCLC with radiotherapy (RT) and/or chemotherapy (CHT) and metastatic disease with CHT, but the evidence for these approaches is based on studies which are usually performed with highly selected patients while elderly patients are under-represented. We used the data from studies addressing particularly elderly or providing subgroup information on age to analyse the feasibility of current standard approaches for elderly and discuss alternative approaches. Surgery is an effective method in elderly patients with early stage NSCLC although some approaches bear a somewhat higher risk of operative morbidity and mortality. RT for early stage may be an alternative with curative potential. For locally advanced stage RT alone, or combined radiochemotherapy in selected cases, is feasible for elderly patients with locally advanced NSCLC when a careful assessment of pre-therapeutic status is made and appropriate drugs are selected. Advanced age alone also should not preclude CHT, although the risk of adverse effect may be higher in certain cases. New generation drugs seem to be particularly feasible and efficient in elderly patients. In general, age itself does not seem to preclude patients from standard treatments although in some cases co-morbidity forces to alternative approaches. Currently, single-agent CHT should be considered as the standard treatment of advanced NSCLC elderly patients.
机译：有一个全球的趋势老年人口的增加发病率。癌症是最大的风险因素;因此,这是主要的人口转变增加癌症发病率的原因。癌症是一个典型的疾病的老年人病人。治疗非小细胞肺癌(NSCLC)在老年人中。用激进的治疗手术,局部晚期非小细胞肺癌放疗(RT)和/或化疗(十)和转移性疾病,但是这些方法是基于研究证据这通常和高度选择执行吗病人在老年患者未被充分代表。解决特别是老年人或提供子群年龄分析的信息现有标准方法的可行性老年人和讨论替代方法。老年手术是一种有效的方法早期非小细胞肺癌患者尽管一些方法承担更高的风险的发病率和死亡率。阶段可能与治疗的另一种选择的潜力。或结合radiochemotherapy在选定的情况下,老年患者局部可行吗晚期非小细胞肺癌时仔细的评估pre-therapeutic状态和适当的药物选择。不应该排除,虽然的风险在某些情况下不利影响可能更高。新一代药物似乎特别在老年患者可行和有效的。一般,年龄本身似乎并没有阻止病人虽然在从标准治疗某些情况下伴随疾病部队的选择方法。作为先进的标准治疗非小细胞肺癌老年病人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号